Compare KLA Corp. (KLAC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Repligen Corporation Common Stock — how do they compare? KLA Corp. trades at $173.88 (market cap $233.35B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: KLA Corp. is far larger — about 20.6× Repligen Corporation Common Stock's market cap, and KLA Corp. pays a 0.51% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Repligen Corporation Common Stock for 0 Days on average.
| KLAC | RGEN | |
|---|---|---|
Market Cap | $233.35B | $11.31B |
Volume | 14,457,699 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $301.71 | $194.57 |
52-Week Low | $108.70 | $102.87 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $234.60B | $11.20B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $184.00, down 3.22% on the day, with strong technical support at $185. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, continuing a pattern of earnings outperformance. Revenue reached $12.16B in 2025 with impressive 35.57% net income margin and 87.5% ROE, though valuation multiples remain elevated with P/E at 48.86. Recent news highlights AI-driven demand growth and a $12.57B backlog supporting revenue visibility.
Outlook remains positive with analyst consensus price target of $223.88 suggesting 22% upside potential. Investment opportunity centers on AI infrastructure growth and advanced packaging demand, though risks include competitive pressures from AMAT and ASML, high valuation multiples, and potential margin compression. The company's capital return program targeting over 90% of free cash flow provides shareholder support.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
